T1	Gene_or_protein	18 50	epidermal growth factor receptor
T2	Gene_or_protein	53 59	EGFR )
T3	Chemical	65 86	monoclonal antibodies
T4	Chemical	105 131	inhibitors of the tyrosine
T5	Gene_or_protein	105 152	inhibitors of the tyrosine kinase ( TK ) domain
T6	Chemical	105 173	inhibitors of the tyrosine kinase ( TK ) domain of the receptor have
T7	Pharmacodynamic_phenotype	217 249	antitumor activities in patients
T8	Disease	255 293	non-small-cell lung cancer ( NSCLC ) .
R1	isEquivalentTo	Arg1:T1	Arg2:T2
R2	isAssociatedWith	Arg1:T1	Arg2:T3
R3	isAssociatedWith	Arg1:T1	Arg2:T4
R4	isAssociatedWith	Arg1:T1	Arg2:T5
R5	isAssociatedWith	Arg1:T1	Arg2:T6
R6	isAssociatedWith	Arg1:T1	Arg2:T7
R7	isAssociatedWith	Arg1:T1	Arg2:T8
R8	isEquivalentTo	Arg1:T2	Arg2:T1
R9	isAssociatedWith	Arg1:T2	Arg2:T3
R10	isAssociatedWith	Arg1:T2	Arg2:T4
R11	isAssociatedWith	Arg1:T2	Arg2:T5
R12	isAssociatedWith	Arg1:T2	Arg2:T6
R13	isAssociatedWith	Arg1:T2	Arg2:T7
R14	isAssociatedWith	Arg1:T2	Arg2:T8
R15	decreases	Arg1:T3	Arg2:T1
R16	decreases	Arg1:T3	Arg2:T2
R17	influences	Arg1:T3	Arg2:T7
R18	treats	Arg1:T3	Arg2:T8
R19	decreases	Arg1:T4	Arg2:T1
R20	decreases	Arg1:T4	Arg2:T2
R21	influences	Arg1:T4	Arg2:T3
R22	influences	Arg1:T4	Arg2:T5
R23	influences	Arg1:T4	Arg2:T6
R24	influences	Arg1:T4	Arg2:T7
R25	treats	Arg1:T4	Arg2:T8
R26	decreases	Arg1:T5	Arg2:T1
R27	decreases	Arg1:T5	Arg2:T2
R28	influences	Arg1:T5	Arg2:T3
R29	influences	Arg1:T5	Arg2:T4
R30	influences	Arg1:T5	Arg2:T6
R31	influences	Arg1:T5	Arg2:T7
R32	treats	Arg1:T5	Arg2:T8
R33	decreases	Arg1:T6	Arg2:T1
R34	decreases	Arg1:T6	Arg2:T2
R35	influences	Arg1:T6	Arg2:T3
R36	influences	Arg1:T6	Arg2:T4
R37	influences	Arg1:T6	Arg2:T5
R38	influences	Arg1:T6	Arg2:T7
R39	treats	Arg1:T6	Arg2:T8
R40	decreases	Arg1:T7	Arg2:T1
R41	decreases	Arg1:T7	Arg2:T2
R42	influences	Arg1:T7	Arg2:T3
R43	influences	Arg1:T7	Arg2:T4
R44	treats	Arg1:T7	Arg2:T8
R45	decreases	Arg1:T8	Arg2:T1
R46	decreases	Arg1:T8	Arg2:T2
